Clinical Trial Update: Adenovirus Type 35 Based Circumsporozoite Malaria Vaccine in Burkina Faso [Phase 1]

View source ↗

Summary

Phase 1 trial of an Ad35-based circumsporozoite malaria vaccine in Burkina Faso has completed, evaluating safety and immunogenicity.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malaria

Drugs mentioned

• Adenovirus Type 35 Based Circumsporozoite Malaria Vaccine

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Malaria | Phase 1 | Status: COMPLETED